J.B. Chemicals & Pharmaceuticals Ltd.
NSE: JBCHEPHARM · Pharmaceuticals
Snapshot
Unlock J.B. Chemicals & Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
J. B. Chemicals & Pharmaceuticals Limited is a Mumbai-based pharmaceutical company engaged in the manufacturing and marketing of formulations, herbal remedies, and active pharmaceutical ingredients. The company also provides contract manufacturing services and offers a diverse portfolio of therapeutic products, including contrast media for diagnostic imaging.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations, active pharmaceutical ingredients, and diagnostic contrast media. Additionally, it leverages its manufacturing capabilities to provide contract manufacturing services for various dosage forms to third-party clients.
- Incorporation Year:1976
Growth Outlook
Growth is expected to be driven by the expansion of its therapeutic presence in segments such as gastroenterology, hypertension, and diabetes. The company continues to focus on its contract manufacturing capabilities and international market penetration to scale operations.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by global health authorities like the USFDA.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines in India may impact profit margins.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients could disrupt production schedules.
- Currency Risk. As an exporter, the company is exposed to foreign exchange volatility which may affect its international revenue realisations.
Start your research today
Unlock AI insights, financials, peers and live data on J.B. Chemicals & Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹4,148 Cr
TTM · consolidated
NET PROFIT
₹709 Cr
TTM · consolidated
EPS
₹45.26
TTM · consolidated
RETURN ON EQUITY
18.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.9%
TTM · consolidated
P/E
53.2x
Q4 FY26 · consolidated
EBITDA MARGIN
28.1%
TTM · consolidated
NET PROFIT MARGIN
11.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
J.B. Chemicals & Pharmaceuticals Ltd.JBCHEPHARM | — | 53.22 | — | 5.9% | 28.1% | 18.7% | 23.9% | — |
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.56L Cr | 37.68 | 22.41 | 11.4% | 33.5% | 15.6% | 20.5% | +20.0% |
Divi's Laboratories Ltd.DIVISLAB | ₹2.42L Cr | 82.57 | 54.64 | 16.3% | 39.3% | 18.4% | 23.1% | +48.4% |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.85L Cr | 77.59 | 38.74 | 32.9% | 32.6% | 27.0% | 15.1% | +34.9% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.13L Cr | 24.96 | 14.08 | 21.1% | 30.7% | 18.0% | 20.1% | +10.7% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 33.18 | 18.12 | 1.8% | 21.6% | 10.2% | 13.6% | -12.2% |
As of Q4 FY26
Financials
J.B. Chemicals & Pharmaceuticals Ltd.
NSE: JBCHEPHARM · Pharmaceuticals
Snapshot
Unlock J.B. Chemicals & Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
J. B. Chemicals & Pharmaceuticals Limited is a Mumbai-based pharmaceutical company engaged in the manufacturing and marketing of formulations, herbal remedies, and active pharmaceutical ingredients. The company also provides contract manufacturing services and offers a diverse portfolio of therapeutic products, including contrast media for diagnostic imaging.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations, active pharmaceutical ingredients, and diagnostic contrast media. Additionally, it leverages its manufacturing capabilities to provide contract manufacturing services for various dosage forms to third-party clients.
- Incorporation Year:1976
Growth Outlook
Growth is expected to be driven by the expansion of its therapeutic presence in segments such as gastroenterology, hypertension, and diabetes. The company continues to focus on its contract manufacturing capabilities and international market penetration to scale operations.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by global health authorities like the USFDA.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines in India may impact profit margins.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients could disrupt production schedules.
- Currency Risk. As an exporter, the company is exposed to foreign exchange volatility which may affect its international revenue realisations.
Start your research today
Unlock AI insights, financials, peers and live data on J.B. Chemicals & Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹4,148 Cr
TTM · consolidated
NET PROFIT
₹709 Cr
TTM · consolidated
EPS
₹45.26
TTM · consolidated
RETURN ON EQUITY
18.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.9%
TTM · consolidated
P/E
53.2x
Q4 FY26 · consolidated
EBITDA MARGIN
28.1%
TTM · consolidated
NET PROFIT MARGIN
11.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26